Table 3. Cytogenetic findings in tested patients with ATLL.

Subtype	Age/ Gender	Source	Karyotype
Acute	39 / F	BM	48~49, XX, +X, del(1)(p34), add(2)(p11.2), del(3)(q21), dic(3:3)(q21;p21), del(5)(q13q33), del(7)(p13), +8, del(9)(p13), dup(11)(q13q23), −12, −15, −16, −17, add(19)(p13.3), −20, +22
Acute	42 / M	BM	44, X, -Y, −6, der(13)t(13;14)(q10;q10), +mar
Acute	69 / M	BM	48~49, XY, +X, t(1;7)(q32;q36), add(9)(p24), t(11;19)(q13;p13.3), add(14)(p10), +14, add(20)(q11.2), del(20)(q11.2), +20
Acute	35 / M	PB	45~48, X, -Y, der(1)t(1;10)(q21;p11.2), t(1;11)(q22;q24), +der(1)del(1)(q21q42), +3, −4, del(6)(q13q22), add(7)(q36), del(8)(q22q24.3), −10, add(12)(q24.3), +del(12)(q13q14), −14, −15, −16, −17, −19, −20, +21, +21, +22, +22, +2mar
Acute	51 / M	BM	46, XY, del(11)(q23)
Acute	44 / M	BM	46, Y, t(X;9) (p22.1;p13), t(1;20) (p22;q11.2), t(2;15) (q33;p12)
Acute	60 / F	BM	46, XX, 14q11.2 and 14q32 polysomy on FISHa
Acute	36 / M	BM	47-48, XY, der(2)t(1;2) (q21;q35), add(3)(p21), del (3) (q21), +3, del (6) (q23), −9, −9, −10, add (14) (q32), +1-3mar
Acute	43 / M	PB	48, XY, del(6)(p22), +7, +14, −17, +3mar
Acute	58 / F	BM	47, XX, t(1;13)(p36.3;q33), dup(2)(p11.2p14), t(4:9)(q34;q31.1), t(15;19)(p11.2;q13.2), +19
Acute	54 / F	BM	84~85, XX, add(3)(q12)x2, +3, add(4)(q31), −4, del(5)(q15q33)x2, −7, add(9)(p13)x2, −10, −10, −11, add(11)(p15), −12, −13, −13, −13, add(13)(p10), −14, i(14)(q10), −15, add(15)(p10), −19, −19, −20, add(20)(q13.3)x2, i(21)(q10)x2, +10mar
Acute	56 / F	BM	45-46, X, add(X)(q22), t(11;15) (p11.2;q12), del(12) (p12), add(14) (p11.2), −16, −17, −22, +mar
Lymphomatous	62 / F	BM	46, XX, del(20)(q11,.2)

^aFluorescent in situ hybridization, this patient had a history of Philadelphia chromosome positive chronic myelogenous leukemia.

BM: bone marrow; PB: peripheral blood.

(n=13).